HR
RVNC

Howe & Rusling’s Revance Therapeutics, Inc. RVNC Stock Holding History

Howe & Rusling’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-45
Closed -$1K – 1080
2021
Q3 		$1K Buy
45
+13
+41% +$371 ﹤0.01% 955
2021
Q2 		$1K Hold
32
– – ﹤0.01% 921
2021
Q1 		$1K Sell
32
-5
-14% -$138 ﹤0.01% 927
2020
Q4 		$1K Buy
+37
New +$958 ﹤0.01% 912
2016
Q3 		– Sell
-21
Closed – – 1136
2016
Q2 		$0 Hold
21
– – ﹤0.01% 1063
2016
Q1 		$0 Hold
21
– – ﹤0.01% 1068
2015
Q4 		$1K Hold
21
– – ﹤0.01% 948
2015
Q3 		$1K Hold
21
– – ﹤0.01% 968
2015
Q2 		$1K Buy
+21
New +$540 ﹤0.01% 987

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Howe & Rusling's RVNC Position: Q4 2021 in Review

Howe & Rusling sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 45 shares — an estimated $1K sold.

Howe & Rusling first reported a position in RVNC in Q2 2015 and held it in 9 quarters. The position peaked at $1K in Q3 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

  • Howe & Rusling reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Howe & Rusling sold 45 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $1K.
  • Howe & Rusling first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 9 quarters.
  • Howe & Rusling's Revance Therapeutics, Inc. position peaked at $1K in Q3 2021.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on Howe & Rusling's 13F filing for Q4 2021, filed 14 Feb 2022.